Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 8:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 222 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo powder capsules Clear all
Completed Phase 2 Interventional

Randomized, Double-blind, Placebo Controlled Phase II Study to Examine the Effects of DAS181 in Healthy Adult Subjects With Laboratory Confirmed Influenza

NCT01037205
View directory record Official record
Conditions
Influenza
Interventions
DAS181 dry powder, formulation F02, Respitose ML006 (DMV-Fonterra)
Drug
Lead sponsor
Ansun Biopharma, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
42
States / cities
Carmichael, California • Chula Vista, California • La Mesa, California + 39 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2014 · Synced Oct 1, 2026, 8:09 AM EDT
Completed Phase 3 Interventional Results available

1-year Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Chronic Obstructive Pulmonary Disease (COPD)

NCT00929110
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Glycopyrronium bromide, Placebo to glycopyrronium bromide, Tiotropium
Drug
Lead sponsor
Novartis
Industry
Eligibility
40 Years and older
Enrollment
1,066 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
75
States / cities
Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 68 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2012 · Synced Oct 1, 2026, 8:09 AM EDT
Completed Phase 2 Interventional Results available

A Study of the Efficacy of Canakinumab in Prevention of Acute Flares in Chronic Gout Patients Initiating Allopurinol Therapy (Core Study) and a Long-term Study of the Efficacy and Safety of Canakinumab in Patients With Gout (Extension Study)

NCT00819585
View directory record Official record
Conditions
Gout
Interventions
Canakinumab, Colchicine, Allopurinol, Placebo Matching Canakinumab, Placebo Matching Colchicine
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
432 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
19
States / cities
Huntington Beach, California • San Diego, California • Jupiter, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2018 · Synced Oct 1, 2026, 8:09 AM EDT
Terminated Not applicable Interventional Results available

Prophylactic Use of Postpartum Sertraline to Prevent Postpartum Depression

NCT02235064
View directory record Official record
Conditions
Depression, Postpartum
Interventions
Sertraline, Placebo
Drug
Lead sponsor
The Cooper Health System
Other
Eligibility
18 Years and older · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Camden, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Oct 1, 2026, 8:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Quantifiably Determine if the Botanical Formulation, LLP-01, Has a Significant Clinical Effect on Proteomic Inflammatory and Cardiovascular Biomarkers in Healthy, Older Individuals.

NCT06065241
View directory record Official record
Conditions
Aging, Inflammation
Interventions
LLP-01, Placebo
Dietary Supplement · Other
Lead sponsor
LL Prosper Inc.
Industry
Eligibility
50 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Oct 1, 2026, 8:09 AM EDT
Completed Phase 3 Interventional

Bioequivalence Study of Tiotropium 18 μg Inhalation Powder, Hard Capsule With Spiriva®Handihaler® 18 μg Inhalation Powder, Hard Capsule in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT05986591
View directory record Official record
Conditions
COPD
Interventions
Test Product - Tiotropium Bromide Inhalation Powder 18 mcg, Spiriva Handihaler (Tiotropium Bromide) 18 mcg, Placebo
Combination Product
Lead sponsor
Xiromed LLC
Industry
Eligibility
40 Years to 75 Years
Enrollment
335 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
24
States / cities
Los Angeles, California • Fort Myers, Florida • Gainesville, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2024 · Synced Oct 1, 2026, 8:09 AM EDT
Completed Phase 2 Interventional

Herbal Treatment for Attention Deficit Hyperactivity Disorder (ADHD)

NCT00100295
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Hypericum perforatum, Placebo
Drug · Other
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
6 Years to 17 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Kenmore, Washington
Source: ClinicalTrials.gov public record
Updated Oct 26, 2007 · Synced Oct 1, 2026, 8:09 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of QVA149 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT00570778
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
indacaterol/glycopyrrolate, indacaterol, placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
3
States / cities
St Louis, Missouri • Charlotte, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 26, 2018 · Synced Oct 1, 2026, 8:09 AM EDT
Terminated Phase 2 Interventional Results available

Oral Immunotherapy for Desensitization in Children, Adolescents, and Young Adults With Hen Egg Allergy

NCT04056299
View directory record Official record
Conditions
Hen Egg Allergy
Interventions
AR201 powder, Placebo powder
Biological
Lead sponsor
Aimmune Therapeutics, Inc.
Industry
Eligibility
4 Years to 26 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
11
States / cities
Little Rock, Arkansas • Rolling Hills Estates, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2022 · Synced Oct 1, 2026, 8:09 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Allergic Disease Onset Prevention Study

NCT05003804
View directory record Official record
Conditions
Atopic Dermatitis, Type 1 Hypersensitivity
Interventions
STMC-103H, Placebo
Biological
Lead sponsor
Siolta Therapeutics, Inc.
Industry
Eligibility
0 Days to 14 Days
Enrollment
283 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
24
States / cities
Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Oct 1, 2026, 8:09 AM EDT
Completed Phase 3 Interventional Results available

Safety Study of the Effects of Inhaled Fluticasone Furoate/GW642444 on the Hypothalamic-Pituitary-Adrenal (HPA) Axis

NCT01086410
View directory record Official record
Conditions
Asthma
Interventions
Placebo Inhalation Powder, Fluticasone Furoate/GW642444 Inhalation Powder, Placebo Oral Capsule, Prednisolone Oral Capsule
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years to 65 Years
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
4
States / cities
Cypress, California • Huntington Beach, California • Oklahoma City, Oklahoma + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2017 · Synced Oct 1, 2026, 8:09 AM EDT
Terminated Phase 3 Interventional Results available

Study to Assess the Safety and Efficacy of ONZETRA® Xsail® for the Acute Treatment of Episodic Migraine With or Without Aura in Adolescents

NCT03338920
View directory record Official record
Conditions
Acute Migraine With or Without Aura
Interventions
sumatriptan nasal powder, Placebo
Drug
Lead sponsor
Currax Pharmaceuticals
Industry
Eligibility
12 Years to 17 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
40
States / cities
Phoenix, Arizona • Anaheim, California • Los Angeles, California + 33 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2023 · Synced Oct 1, 2026, 8:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Study of Chokeberry to Reduce Cardiovascular Disease Risk in Former Smokers

NCT01541826
View directory record Official record
Conditions
Cardiovascular Disease, Oxidative Stress
Interventions
Chokeberry Extract, Placebo capsule, Chokeberry extract capsule, acute
Dietary Supplement
Lead sponsor
University of Connecticut
Other
Eligibility
18 Years to 65 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Storrs, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Oct 1, 2026, 8:09 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Different Doses of Indacaterol in Chronic Obstructive Pulmonary Disease (COPD)

NCT01089127
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Indacaterol, Salmeterol 50 μg, Placebo to indacaterol, Placebo to salmeterol
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
552 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
69
States / cities
Florence, Alabama • Jasper, Alabama • Phoenix, Arizona + 63 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2011 · Synced Oct 1, 2026, 8:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effects of Mirtoselect®, Virtiva®, and Enovita® on Cognitive Performance and Mood States

NCT06309914
View directory record Official record
Conditions
Mental Processes, Cognitive Change, Mood Change
Interventions
Placebo, Enovita Grape Seed Extract, Mirtoselect Bilberry Extract, Virtiva Plus Ginko Biloba Extract
Dietary Supplement
Lead sponsor
Applied Science & Performance Institute
Industry
Eligibility
25 Years to 55 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 30, 2024 · Synced Oct 1, 2026, 8:09 AM EDT
Completed Phase 2 Interventional Results available

LIPS-A: Lung Injury Prevention Study With Aspirin

NCT01504867
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome
Interventions
Aspirin, Lactose powder
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
16
States / cities
Stanford, California • Bridgeport, Connecticut • Gainsville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2017 · Synced Oct 1, 2026, 8:09 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)

NCT07481981
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Treprostinil Palmitil Inhalation Powder, Placebo
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
8
States / cities
Los Angeles, California • Santa Barbara, California • Torrance, California + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 1, 2026, 8:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Omega-3 and Blueberry Supplementation in Age-Related Cognitive Decline

NCT01746303
View directory record Official record
Conditions
Age-related Memory Disorders, Mood Disorders
Interventions
Omega-3 fatty acid, Blueberry powder, Placebo oil, Placebo powder
Dietary Supplement · Other
Lead sponsor
University of Cincinnati
Other
Eligibility
62 Years to 80 Years
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2016
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 27, 2016 · Synced Oct 1, 2026, 8:09 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Caffeine and Cerebrovascular Reactivity

NCT04730193
View directory record Official record
Conditions
Caffeine
Interventions
Caffeine, Placebo
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
21 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Aug 9, 2022 · Synced Oct 1, 2026, 8:09 AM EDT
Not yet recruiting Phase 2 Interventional Accepts healthy volunteers

Trial of the Combination of Alpha-Lipoic Acid and Mirabegron in Women and in Men With Obesity

NCT05713799
View directory record Official record
Conditions
Insulin Resistance, Obesity
Interventions
Alpha-lipoic acid, Mirabegron, Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 1, 2026, 8:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effects of Tyrosol and Creatine on Endurance, Strength, and Fatigue Resistance in Healthy Adults

NCT06883292
View directory record Official record
Conditions
Tyrosol, Creatine, Endurance Performance, Cognition
Interventions
Tyrosol, Creatine, Resistant Dextrin
Dietary Supplement
Lead sponsor
Applied Science & Performance Institute
Industry
Eligibility
18 Years to 50 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Oct 1, 2026, 8:09 AM EDT
Completed Not applicable Interventional

Betaine, Exercise Performance, and Gut Permeability

NCT06392360
View directory record Official record
Conditions
Metabolic Disturbance, Permeability; Increased
Interventions
Betaine, Placebo
Dietary Supplement
Lead sponsor
Appalachian State University
Other
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Kannapolis, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Oct 1, 2026, 8:09 AM EDT
Withdrawn Phase 2Phase 3 Interventional

Effect of D-cycloserine on a Short Imagery Rescripting Intervention for Subclinical PTSD

NCT03216356
View directory record Official record
Conditions
PTSD
Interventions
CBT + ImRs, CBT + I.E., D-Cycloserine, Placebo, Study Pill
Behavioral · Drug
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 1, 2026, 8:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Dose Study of PF-04991532 in Healthy Subjects

NCT01102673
View directory record Official record
Conditions
Diabetes Mellitus, Diabetes Mellitus, Type 2, Glucose Metabolism Disorders
Interventions
PF-04991532, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 5, 2010 · Synced Oct 1, 2026, 8:09 AM EDT